Lexicon Pharmaceuticals (LXRX) vs Sagimet Biosciences Series A (SGMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sagimet Biosciences Series A (SGMT) has outperformed Lexicon Pharmaceuticals (LXRX) over the past year, gaining 36.1% versus a gain of 14.2%. Lexicon Pharmaceuticals is the larger company by market cap ($681.2 million vs $648.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LXRX | SGMT |
|---|---|---|
| Share price | $1.53 | $9.08 |
| Market cap | $681.21M | $648.02M |
| 1-day change | -8.38% | -5.61% |
| YTD return | +33.04% | +53.38% |
| 1-year return | +14.18% | +36.13% |
| 5-year return | -67.72% | — |
| EPS (TTM) | $-0.15 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $49.80M | — |
| Revenue growth (YoY) | +60.24% | — |
| Net income (latest FY) | $-50.34M | $-51.04M |
| Gross margin | 99.45% | — |
| Operating margin | -98.21% | — |
| Net margin | -101.08% | — |
| 52-week high | $2.68 | $11.45 |
| 52-week low | $1.10 | $4.50 |
| Distance from 52-week high | -42.91% | -20.69% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +195.42% | +200.33% |
| Average volume | 2.56M | 1.23M |
| Shares outstanding | 445.23M | 71.37M |
| Employees | 81 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SGMT has outperformed LXRX by 22.0 percentage points over the past year.
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
LXRX vs SGMT FAQ
Which is bigger, Lexicon Pharmaceuticals or Sagimet Biosciences Series A?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $681.21M compared with $648.02M for Sagimet Biosciences Series A (SGMT).
Which stock has performed better over the past year, LXRX or SGMT?
SGMT returned +36.13% over the past 12 months, compared with +14.18% for LXRX (price return, excluding dividends). Past performance does not predict future results.
Are Lexicon Pharmaceuticals and Sagimet Biosciences Series A in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.